Robert Lahasky, MD
Family Medicine · New Iberia, LANPI 1922086339
Payments from drug & device makers
Across 659 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$926
- Boehringer Ingelheim$909
- Lilly USA, LLC$847
- Amgen$719
- plus $5K from 32 others
What the payments were for
- Food & beverage$12,717100%
- Education$540%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $2,352 |
| AstraZeneca | 58 | $1,990 |
| Novo Nordisk | 67 | $926 |
| Boehringer Ingelheim | 52 | $909 |
| Lilly USA, LLC | 61 | $847 |
| Amgen | 36 | $719 |
| Johnson & Johnson | 25 | $678 |
| GSK | 40 | $666 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $388 |
| Corium, LLC | 21 | $352 |
| Bayer | 19 | $332 |
| Astellas Pharma US Inc | 20 | $301 |
| Pfizer | 16 | $240 |
| Sanofi-aventis U.S. LLC | 13 | $203 |
| Merck | 12 | $181 |
| Idorsia Pharmaceuticals US Inc | 7 | $178 |
| Dexcom, Inc. | 9 | $149 |
| Teleflex LLC | 1 | $132 |
| Abbott | 6 | $122 |
| Verona Pharma, Inc. | 1 | $122 |
| Eisai Inc. | 6 | $104 |
| Gilead | 1 | $100 |
| Coloplast | 1 | $99 |
| Phathom Pharmaceuticals, Inc. | 5 | $96 |
| Amarin Pharma, Inc. | 5 | $84 |
| Biogen | 5 | $75 |
| Novartis | 5 | $70 |
| Sanofi Pasteur Inc. | 5 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| Exact Sciences | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Almatica Pharma LLC | 1 | $27 |
| VBI Vaccine (delaware) Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,771 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 148 | $140,036 |
| FarxigaDapagliflozin Propanediol | 136 | $129,899 |
| JanuviaSitagliptin Phosphate | 80 | $78,026 |
| OzempicSemaglutide | 40 | $44,468 |
| LinzessLinaclotide | 52 | $40,107 |
| EliquisApixaban | 41 | $38,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $30,745 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $27,284 |
| MounjaroTirzepatide | 14 | $23,908 |
| TradjentaLinagliptin | 24 | $23,876 |
| XareltoRivaroxaban | 18 | $21,306 |
| KerendiaFinerenone | 15 | $20,751 |
| VraylarCariprazine Hcl | 13 | $18,909 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $16,946 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $16,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $909 | $163,911172 claims |
| AstraZenecaFarxiga | $1,990 | $129,899136 claims |
| MerckJanuvia, Janumet Xr, Steglatro | $181 | $87,927103 claims |
| AbbVieLinzess, Vraylar, Synthroid | $2,352 | $61,156104 claims |
| Novo NordiskOzempic | $926 | $44,46840 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $666 | $41,47865 claims |
| Lilly USA, LLCMounjaro, Trulicity | $847 | $39,37228 claims |
| PfizerEliquis | $240 | $38,84341 claims |
| Johnson & JohnsonXarelto | $678 | $21,30618 claims |
| BayerKerendia | $332 | $20,75115 claims |
| Astellas Pharma US IncMyrbetriq | $301 | $11,88014 claims |
| NovartisEntresto | $70 | $8,53011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in New Iberia
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.